Utama › Karsinoma Urotelial (Sel Transisi) › Minnesota
Kajian klinikal Karsinoma Urotelial (Sel Transisi) di Minnesota
7 kajian untuk Karsinoma Urotelial (Sel Transisi) sedang mencari peserta di lokasi di Minnesota.
Bandar di Minnesota
Teks kajian rasmi (Bahasa Inggeris)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #68, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- dan 10 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06524544Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- Fairview Southdale Hospital, Edina
- dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Mayo Clinic Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- Research Site, Rochester
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07815665A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.